Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Unveiling the Enigma: Exploring the Influences of Sexual Hormones in Adpkd Women and the Urgency for Novel Insight

Micaela Petrone
* ,
Martina Catania
* ORCID logo ,
Liliana Italia De Rosa
,
Rebecca S. Degliuomini
,
Kristiana Kola
,
Chiara Lupi
,
Matteo Brambilla Pisoni
,
Stefano Salvatore
,
Massimo Candiani
,
Giuseppe Vezzoli
ORCID logo ,
Maria Teresa Sciarrone Alibrandi
Version 1 : Received: 22 December 2023 / Approved: 25 December 2023 / Online: 26 December 2023 (01:32:02 CET)

A peer-reviewed article of this Preprint also exists.

Petrone, M.; Catania, M.; De Rosa, L.I.; Degliuomini, R.S.; Kola, K.; Lupi, C.; Brambilla Pisoni, M.; Salvatore, S.; Candiani, M.; Vezzoli, G.; Sciarrone Alibrandi, M.T. Role of Female Sex Hormones in ADPKD Progression and a Personalized Approach to Contraception and Hormonal Therapy. J. Clin. Med. 2024, 13, 1257. Petrone, M.; Catania, M.; De Rosa, L.I.; Degliuomini, R.S.; Kola, K.; Lupi, C.; Brambilla Pisoni, M.; Salvatore, S.; Candiani, M.; Vezzoli, G.; Sciarrone Alibrandi, M.T. Role of Female Sex Hormones in ADPKD Progression and a Personalized Approach to Contraception and Hormonal Therapy. J. Clin. Med. 2024, 13, 1257.

Abstract

This in-depth review navigates the intricate relationship between gender, hormonal influences, and the progression of autosomal dominant polycystic kidney disease (ADPKD), highlighting the limited literature on this crucial topic. The study explores the impact of female sex hormones on liver and renal manifestations, uncovering gender-specific differences in disease progression. Actually hormonal therapy in women with ADPKD remains a challenging issue and is a source of concern regarding its potential impact on disease outcomes, particularly at the hepatic level. Notably, women with ADPKD exhibit a slower renal disease progression compared to men, attributed to hormonal dynamics. The review sheds light on the role of estrogen in regulating pathways of the renin-angiotensin-aldosterone system, revealing its complex interplay and implications for cardiovascular and renal health. Therapeutic considerations for fertile women with ADPKD, including contraception options, are discussed, emphasizing the necessity for personalized approaches. In the postmenopausal phase, the review evaluates the role of hormonal replacement therapy, considering its potential benefits and risks in the context of ADPKD. The review concludes by underscoring the imperative need for tailored treatment approaches for ADPKD patients, considering individual risks and benefits. The scarcity of literature underlines the call for further research to enhance our understanding of optimal hormonal therapies in the context of ADPKD, ultimately paving the way for innovative and personalized therapeutic interventions.

Keywords

ADPKD; CKD; RAAS; female sexual hormones; hepatomegaly; childbearing age; postmenopausal; contraception; HRT

Subject

Public Health and Healthcare, Primary Health Care

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.